의약품안전나라

국가
검색어
제제

※ 출처: ClinicalTrials.gov

총 7건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, NCT No, 개시일자
순번	임상시험 제목	적응증	연구설계	의뢰자/실시기관	임상단계	NCT No	개시일자
1	Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)	Covid19	Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant\|Biological: Saline placebo	Cinnagen\|Vaxine Pty Ltd	Phase 3	NCT05005559	2021-08-07
2	CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)	Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)\|Refractory B Cell Acute Lymphoblastic Leukemia (ALL)	Biological: CD19 CAR engineered autologous T-cells\|Drug: Cyclophosphamide\|Drug: Fludarabine\|Drug: Mesna	Sabz Biomedicals\|Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran\|Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran	Phase 1	NCT04653493	2021-08-00
3	Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)	Covid19	Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant\|Biological: Saline placebo	Cinnagen\|Vaxine Pty Ltd	Phase 2	NCT04944368	2021-05-30
4	Efficacy and Safety of Xacrel짰 (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis\|Relapsing-Remitting	Biological: Ocrelizumab (CinnaGen, Iran)\|Biological: Ocrelizumab (Roche, Switzerland)	Cinnagen	Phase 3	NCT04966338	2019-08-19
5	Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors	Hemophilia A or B With Inhibitor	Biological: Biosimilar eptacog alfa, activated (AryoSeven)\|Biological: Eptacog alfa, activated (Novoseven)	AryoGen Pharmed Co.	Phase 3	NCT03935334	2018-07-23
6	Autologous Killer Cell Therapy in Colon Cancer Patients	Colon Cancer Stage II/III	Biological: Cytokine-induced killer cell\|Other: Chemotherapy AND/OR Radiation Therapy	Sabz Biomedicals\|Ministry of Health and Medical Education\|Cell-based Therapies Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran	Phase 1\|Phase 2	NCT03329664	2018-01-01
7	Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven짰, in Patients With Congenital Factor VII Deficiency	Factor VII Deficiency	Biological: Eptacog alfa, biosimilar and reference medicinal product Novoseven\|Biological: Eptacog alfa biosimilar	AryoGen Pharmed Co.	Phase 3	NCT03079063	2017-03-01